BIOC360003_1[1].ppt
Why are new drugs and cheaper, more user friendly regimes needed?
Achieving a ‘Grand Convergence’ in Global Health Chair: Richard Feachem, University of California, San Francisco Presenter: Dean Jamison, University of.
Community based research for improved TB services Esau Kekeubata 1, Rowena Asugeni 1, Peter Massey 2, John Wakageni 1, Tommy Esau 1, David MacLaren 3,
Multi-drug Resistant Tuberculosis Hail M. Al-Abdely Consultant, Infectious Diseases, KFSH&RC.
Infectious Diseases for the Medicine Boards Christopher Hurt, MD Division of Infectious Diseases June 2010.
Key Findings and Recommendations External review to TB Prevention, Control and Care in the Republic of Kazakhstan Astana, 16 May 2013 Dr Masoud Dara Programme.
1997-2009. 1997-1999 - CRDF, GN1-432 Clinical and Molecular Epidemiology of TB in the Republic of Georgia – Emory University, Atlanta, GA,USA 2000-2001-CRDF,
BUG & SUPERBUG (with apologies to George Bernard Shaw)
New Antituberculous Drugs Hail M. Al-Abdely, MD Consultant, Infectious Diseases King Faisal Specialist Hospital and Research Center.
New Antituberculous Drugs
The Future of Drug-Resistant TB: How Do We Prevent a Nightmare? (HINT: By Treating It!) David Dowdy, MD PhD B. Frank Polk Assistant Professor of Epidemiology.